عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

‘Ahlam Alasr' Film Achieves Remarkable Success at Red Sea Festival Premiere

The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA
The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA
TT
TT

‘Ahlam Alasr' Film Achieves Remarkable Success at Red Sea Festival Premiere

The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA
The film is produced by Tape Productions in collaboration with the Red Sea Fund, and is directed by Fares Godus, starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma. SPA

Funded by the Saudi Cultural Development Fund, the film `Ahlam Alasr' attracted audiences at its premiere at the third annual Red Sea International Film Festival. The film’s premiere tickets were sold out within five days of the festival, and the movie garnered wide acclaim from both critics and the audience.
The film tells a unique story, exploring the depths of emotions and challenges faced by individuals in their daily lives. The story revolves around a retired football player who was famous before the internet came into existence. Along with his influencer daughter, he decides to seize an opportunity for revenge against those who wronged them. Together they embark on a toxic journey.
After the success of their first film “Shams Al-Ma'arif,” the Godus brothers impressed us again with their new film “Ahlam Alasr” and excelled in the film's direction, production, and acting. Director Fares Godus showcased precision in presenting the film, skillfully transporting the audience into a world of captivating details and events. The audience was also impressed and captivated by producer and lead character Sohayb Godus’ brilliant acting performance as well as Najm’s ability to inhabit the character she is playing.

“We are delighted with the support received from the Cultural Fund to bring our story to life and create something that lives up to the standards of the Saudi film sector. We are proud of the warm reception at the Red Sea International Film Festival, and we look forward to sharing this story with more audiences worldwide,” said Director Fares.

The film “Ahlam Alasr” is funded by the Cultural Development Fund through its Cultural Projects Incentive Program. Launched two years ago in partnership with the Quality of Life Program, the fund allocated a budget of SAR181 million to provide non-recoupable financing for projects in the cultural sectors, including film, to meet the needs of the cultural sector and contribute to its development.

The film, produced by Tape Productions in collaboration with the Red Sea Fund, directed by Fares Godus and starring Sohayb Godus, Najm, Fatma AlBanawi, and Hakim Juma, is expected to continue its screenings in other international film festivals. Its local cinema release will take place sometime next year, and the Godus brothers hope to sell international distribution rights soon to further solidify the position of Saudi film on the global stage.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”